Valuation
- Market cap
- 6,273,000
- Revenue TTM
- $0
- Net income TTM
- $-8,770,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 38,700
- Avg volume
- 66,288
- Day's range
- $1.23 – $1.38
- Shares out
- 4,826,000
- Stochastic %K
- 3%
- Beta
- 0.41
- Analysts
- Moderate Buy
- Price target
- $26.00
Company profile
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerati...
Show more
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 844 722 6333
- Website
- https://www.alzamend.com
- Address
- 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States
Latest news
No headlines yet.
